Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung

Executive Summary

The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.

Advertisement

Related Content

US Filing For AZ’s Imfinzi In Stage III Lung Cancer
And Then There Were Five: Roche's Tecentriq Joins Europe I-O Race
AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel